Biomaterials - A Global Market Overview27 Apr 2011 • by Natalie Aster
The range of standards governing such permanent and temporary (bioresorbable) implant improvements is too large to enunciate. On the one hand, where permanent implant materials used for bone or tooth replacement have to be completely inert to bodily fluids, on the other hand, materials utilized for temporary implants have to be degradable at preset rates as required by the targeted area of application. An increase in the demand for biomedical implant materials, propelled by commercialization opportunities offered, has ensued in providing exciting options for developing advanced engineered plastic materials. For instance, DSM Biomedical has lately unveiled plans to develop a new easily crosslinkable UHMWPE material for enhancing the mechanical properties and service life of hip and knee implants. UHMWPE has an ideal replacement in polycarbonatepolyurethane (PCU) for hip implants, which is being considered as an alternative for the elimination of wear issues associated with polymer weight bearing surfaces. Solvay has also been in the forefront of innovation by introducing a range of stock shape rod and plates fabricated from PEEK for medical implant applications, including cardiovascular connectors, spinal implants and pacemaker components. Endolign from Invibio is a biocompatible carbon fiber composite in a PEEK matrix that can be utilized in load-bearing medical implants. Additionally, a biocompatible/biodegradable surgical screw injection molded from PLA composite has been developed by the Fraunhofer Institute.
The report “Biomaterials – A Global Market Overview” by Industry Experts reviews, analyses and projects the Biomaterials market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 8 independent countries across Europe ֠France, Germany, Italy Spain, the United Kingdom and Rest of Europe; Asia-Pacific, China, India, Japan and Rest of Asia-Pacific.
Biomaterials – A Global Market Overview
Published: April 2011
Price: US$ 3,960.00
Report Sample Abstract
Biocompatibility: Keys to Choose the Right Material
Though the procedure of selecting the right polymer for medical devices has remained relatively unchanged over the past decade-and-a-half, there has been an exponential growth in the level of complication. Design engineers are confronted with a surplus of information today, such as the range of specially designed materials, a plethora of suppliers, and accessibility to reference databases. How one applies in solving this conundrum remains a moot question.
Accessing live technical support from suppliers or database providers is not a cakewalk due to staff reductions and department consolidations, in addition to several companies losing experts who could have hitherto provided appropriate data on polymer selection for new applications. Additionally, companies today are not in possession of historical databanks of material expertise or on-staff resources that could steer new project efforts. While extent of knowledge gain has become highly focused, experience level in many companies is on a low. Adding to this is the progression of intricate devices, often combining advances in multiple novel technologies, such as conductive polymers, shape memory materials, drug-eluting devices and polymers that dissolve in the body, which offer little respite in the process of choosing the suitable polymer for a specific application.
KEY GLOBAL PLAYERS. THE UNITED STATES
Established in 2001 with headquarters in Cambridge, Massachusetts, 3DM, Inc, an operating subsidiary of 3DMatrix Japan Ltd since October 2007, is a biomaterials company engaged in the development of medical therapies for expediting wound healing and tissue regeneration for wide ranging medical indications for pharmaceutical companies, biotech labs, and academic laboratories.
The company offers PuraMatrix, which is a peptide hydrogel synthetic matrix material used for creating three-dimensional micro-environments for a range of cell culture and in vivo experiments and for tissue regeneration, cell therapies, and drug delivery system applications. Additional products include PuraMatrixHC high concentration gels with tissue retention and therapeutic delivery properties for cell culture and tissue engineering applications, PuraMatrix with self-assembling domain and functional motif functionalities to improve cell adhesion and cell migration and PuraMatrixGMP clinical-grade gels for orthopedics, bioproduction, and drug delivery. 3DM’s products are used in the fields of orthopedics, cardiac devices, wound healing, and drug and cell delivery.
3M Healthcare is one of the divisions of the global conglomerate, 3M Company, and ranks among the largest providers of medical and surgical products, such as tape, dressings, and surgical drapes. The company also offers Littmann stethoscopes, dental and orthodontic products (the latter through 3M Unitek), drug delivery systems (transdermal patches and inhalers), health information management systems, and microbiological testing and monitoring equipment for the food processing industry. This division was established in 1961 and was initially called Medical Products Division. 3M Healthcare also offers veterinary products, such as casting tapes for large and small animals, wound management tapes and sponges, scrubbers, and adhesives for veterinary and agricultural applications. Despite divesting its branded pharmaceutical division several years back, the company has continued to develop drug delivery systems in collaboration with other pharmaceutical and biotechnology companies.
To order the report or ask for sample pages contact email@example.com